Resistance to Chimeric Antigen Receptor T-Cell Therapy
Chimeric antigen receptor (CAR) T-cells are a form of adoptive immunotherapy constituted of autologous T-cells engineered with a receptors that is able to target tumor antigens. Treatment with CAR19 cells leads to rapid response in a significant proportion of patients with relapsed or refractory aggressive B-cell lymphomas. However, relapses post CAR-T cell therapy are common. In this chapter, we will discuss what is currently known about mechanisms of resistance to CAR-T cell therapy in B-cell lymphomas or leukemias.
KeywordsLymphoma Large B-cell Diffuse; immunotherapy Adoptive; drug resistance Neoplasm
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chimeric Antigen Receptor
CAR-transduced B-cell leukemia
Cytokine Release Syndrome
Diffuse Large B-Cell Lymphoma
Loss Of Heterozygosity
Mantle Cell Lymphoma
Primary Mediastinal B-Cell Lymphoma
Stem Cell Transplant
DLBCL arising from Follicular Lymphoma
The authors would like to thank Erin Morris, RN in her assistance in the preparation of this manuscript.
Disclosure of Conflict of Interest
L.J.M has received research support from Celgene, Janssen, Amgen, and GlaxoSmithKline; honorarium from Celgene, Amgen, Karyopharm, GlaxoSmithKline, and Kite; and speaker fees from Amgen and Sanofi. A.C.X has no conflict of interest to disclose.
- 11.Rivers J, Annesley C, Summers C, Finney O, Pulsipher M, Wayne A, et al. Early response data for pediatric patients wiht non-Hodgkin lymphoma treated with CD19 chimeric antigen receptor (CAR) T-cells. Br J Haematol. 2018;182(Suppl. 1). (23):Abstract 29Google Scholar